Breaking Finance News

Zacks Investment Research downgraded Syros Pharmaceuticals Inc (NASDAQ:SYRS) to Sell in a report released today.

Just yesterday Syros Pharmaceuticals Inc (NASDAQ:SYRS) traded -0.08% lower at $13.25. The company’s 50-day moving average is $11.83 and its 200-day moving average is $12.71. The last stock close price is up 4.02% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Volume of trade was down over the average, with 19,968 shares of SYRS changing hands under the typical 75,110

Zacks Investment Research has downgraded Syros Pharmaceuticals Inc (NASDAQ:SYRS) to Sell in a report released on 9/22/2016.

Performance Chart

Syros Pharmaceuticals Inc (NASDAQ:SYRS)

With a total market value of $0, Syros Pharmaceuticals Inc has with a one year low of $8.16 and a one year high of $21.50 .

Brief Synopsis About Syros Pharmaceuticals Inc (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company's gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets. Its drug programs include SY-1425 and SY-1365. SY-1425 (tamibarotene) is an oral and selective agonist, or activator, of the transcription factor RARa. It is involved in advancing SY-1425 into genomically defined patient populations with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). SY-1365 is a selective small molecule inhibitor of cyclin-dependent kinase 7 (CDK7), a transcriptional kinase. SY-1425 is approved as tamibarotene in Japan for the treatment of acute promyelocytic leukemia (APL), a form of AML. It is developing SY-1365 with a focus on various indications, such as acute leukemia, Small cell lung cancer and Triple negative breast cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *